Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2671 to 2685 of 9044 results

  1. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]

    In development Reference number: GID-TA10979 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]

    In development Reference number: GID-TA11558 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]

    In development Reference number: GID-TA11802 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]

    In development Reference number: GID-TA11254 Expected publication date:  06 August 2026

    Technology appraisal guidance
    In development

  5. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development Reference number: GID-TA11096 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  6. Aggressive behaviour in people receiving NHS or social care: prevention and management

    In development Reference number: GID-NG10432 Expected publication date:  28 January 2027

    NICE guideline
    In development

  7. Frailty: identification and assessment in adults

    Awaiting development Reference number: GID-NG10555 Expected publication date: TBC

    NICE guideline
    Awaiting development

  8. Renal sympathetic denervation for resistant hypertension

    In development Reference number: GID-HTG10527 Expected publication date: TBC

    HealthTech guidance
    In development

  9. Renal sympathetic denervation for resistant hypertension: draft scope consultation

    We are listening to your views on this HealthTech guidance. Comments close 29 June 2026.

    In consultation

  10. Pancreas SABR

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  11. MemoKath Stent Insertion

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  12. Doravirine–islatravir for treating HIV-1 in people with virological suppression on antiretroviral therapy

    Awaiting development Reference number: GID-TA11736 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Doravirine-islatravir for previously untreated HIV-1 infection

    Awaiting development Reference number: GID-TA11734 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Filgotinib for treating axial spondyloarthritis [ID6594]

    In development Reference number: GID-TA11776 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]

    Awaiting development Reference number: GID-TA11744 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development